Forgot Password?
Return to Course Listing

CME: Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care

Activity Description / Statement of Need:

In this online CME self-learning program:


Basal cell carcinoma (BCC) is the most common type of cancer in the United States with over 2 million cases diagnosed annually. Incidence of skin cancer increased during the period of 1976 to 2003 in women less than 40 years old, with no significant increases in the male population. Risk factors of basal cell carcinoma include: exposure to ultraviolet (UV) radiation and eye, skin, and hair color and characteristics. Occupational UV exposure, medium/high UV index geographic regions, and indoor tanning studies have shown increased risk of developing basal cell carcinoma. Unlike other forms of cancer, human papillomavirus and cigarette smoking are not associated with increased risk of basal cell carcinoma.





Introduction, Disclosures

Epidemiology and Risk factors

  • Statistics
  • Risk factors (sun exposure, skin pigmentation)
  • Non factors (smoking, HPV)
  • Age
  • Genetics

Clinical presentation and diagnosis  [Learning Objective #1 and 2]

  • Prevention, Screening (USPSTF recommendations)
  • Physical examination
  • Staging
  • Complications
  • Patient case(s)

Treatment and current/evolving practice guidelines [Learning Objective #3 & 4]

  • Surgical intervention
  • Updates in pharmacological treatment: local and systemic therapy
  • Radiation/photodynamic treatments
  • Adjuvant therapy
  • Barriers to care
  • Patient case(s) [Learning Objective #5]

Personalized patient care and the role of the clinician-patient relationship [Learning Objective #5]

  • How the clinician may help patients recognize the signs and symptoms of disease
  • Tenets of successful physician-patient communication as it relates to treatment options
  • Incorporating patient feedback into the course of care
  • How the clinician might best address patient questions and concerns
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:

Healthcare professionals specializing in: dermatology, dermatologic oncology, medical oncology, and other clinicians who treat patients with BCC.

This program is supported by an educational grant from GENENTECH

Release Date: June 13, 2016 -- Expiration Date: June 13, 2018

Faculty: Robert Phelps, MD


Learning Objectives

By the end of the session the participant will be able to:

  • Describe the challenges associated with diagnosis and treatment of BCC.
  • Apply existing diagnostic recommendations and criteria to practice in the management of BCC.
  • Identify the treatment modalities currently available for management of BCC and apply to patient based cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient based on stage of BCC to optimize safety and efficacy, suggesting modifications for improvement.
  • Describe how the clinician might optimize his/her relationship with BCC patients and those at risk of BCC and apply those principles to patient case(s).



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosure:  Dr. Robert Phelps, MD, Professor of Dermatology and Pathology, Director of Dermatopathology, Icahn School of Medicine is a consultant with Sanofi-Aventis.


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP is an officer and part owner of ScientiaCME, LLC.


Commercial Support Disclosure: This program is supported by an educational grant from GENENTECH


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly- Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

Metastatic Melanoma: Updates from ASCO 2017

Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy

Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies